|
Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040. |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Human Longevity, Inc; Merck; Pfizer |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - Ipsen; Merck; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; Novartis |
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Eisai; Merck Serono; MSD; Novartis; Roche; SOBI |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Bayer; Debiopharm Group; Merck Serono; SOBI |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Ono Pharmaceutical |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Ono Pharmaceutical |
|
|
Honoraria - Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Roche Pharma AG |
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis; Pierre Fabre; Roche |
Research Funding - Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Novartis |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Debiopharm Group; Innate Pharma; Merck Sharp & Dohme; Nanobiotix; Pfizer |
Research Funding - Bayer; Janssen; Novartis; Sanofi |
|
|
Stock and Other Ownership Interests - MaxiVax |
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche |
Research Funding - MaxiVax |
|
|
Stock and Other Ownership Interests - GlaxoSmithKline (I) |
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Innate Pharma |
Research Funding - Genentech |
Travel, Accommodations, Expenses - Mirati Therapeutics |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Debiopharm Group; MedImmune; Merck; VentiRx |
|
|
|
|
Stock and Other Ownership Interests - Merck |
Travel, Accommodations, Expenses - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
Travel, Accommodations, Expenses - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer |
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer |
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer |
Research Funding - AstraZeneca; MSD |
Travel, Accommodations, Expenses - MSD |